Fibrosis can affect any organ and is responsible for up to 45% of all deaths in the
industrialized world. It has long been thought to be relentlessly progressive and irreversible …

Liver fibrosis due to viral or metabolic chronic liver diseases is a major challenge of global
health. Correlating with liver disease progression, fibrosis is a key factor for liver disease …

An increasing percentage of people have or are at risk to develop non-alcoholic fatty liver
disease (NAFLD) worldwide. NAFLD comprises different stadia going from isolated steatosis …

Liver fibrosis and in particular cirrhosis are the major causes of morbidity and mortality of
patients with chronic liver disease. Their prevention or reversal have become major …

Cirrhosis has become the major liver-related clinical endpoint in non-alcoholic
steatohepatitis (NASH). However, progression to cirrhosis is less predictable in NASH than …

Non-alcoholic fatty liver disease—the most common chronic liver disease—encompasses a
histological spectrum ranging from simple steatosis to non-alcoholic steatohepatitis (NASH) …

There is an unmet need for high‐quality liquid biomarkers that can safely and reproducibly
predict the stage of fibrosis and the outcomes of chronic liver disease (CLD). The …

Non-alcoholic fatty liver disease (NAFLD) is reaching epidemic proportions, with a global
prevalence of 25% in the adult population. Non-alcoholic steatohepatitis (NASH), which can …

Emerging evidence suggests that altered components and posttranslational modifications of
proteins in the extracellular matrix (ECM) may both initiate and drive disease progression …

Background & Aims Multiparametric magnetic resonance (MR) imaging has been
demonstrated to quantify hepatic fibrosis, iron, and steatosis. The aim of this study was to …